Assignee
CYCLACEL LTD
GB·44 granted patents·40 pending applications·687 citations·filing 1995–2021
Top patents by PatentIndex Score
84 records- 0195US6972198B2Methods and compositions using protein binding partnersCYCLACEL LTD·Filed 2000·Granted Dec 6, 2005·89 cites·12 claims
- 0292US6531479B2Anti-cancer compoundsCYCLACEL LTD·Filed 2001·Granted Mar 11, 2003·52 cites·23 claims
- 0391US7060506B2Compositions and methods for monitoring the modification of modification dependent binding partner polypeptidesCYCLACEL LTD·Filed 2001·Granted Jun 13, 2006·112 cites·18 claims
- 0491US6699854B2Anti-cancer compoundsCYCLACEL LTD·Filed 2002·Granted Mar 2, 2004·40 cites·26 claims
- 0588US7897605B2Pyrimidine compoundsCYCLACEL LTD·Filed 2008·Granted Mar 1, 2011·14 cites·6 claims
- 0687US8975239B2Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaineCYCLACEL LTD·Filed 2013·Granted Mar 10, 2015·16 cites·15 claims
- 0786US7101967B2Transport vectorsCYCLACEL LTD·Filed 2001·Granted Sep 5, 2006·13 cites·28 claims
- 0886US6670144B1Compositions and methods for monitoring the phosphorylation of natural binding partnersCYCLACEL LTD·Filed 2000·Granted Dec 30, 2003·26 cites·6 claims
- 0984US8349792B2Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agentCYCLACEL LTD·Filed 2007·Granted Jan 8, 2013·3 cites·14 claims
- 1083US6808874B2Methods of monitoring enzyme activityCYCLACEL LTD·Filed 2001·Granted Oct 26, 2004·22 cites·60 claims
- 1182US6472507B1Carrier based drug delivery systemCYCLACEL LTD·Filed 1999·Granted Oct 29, 2002·57 cites·40 claims
- 1281US7582642B2Purine derivativesCYCLACEL LTD·Filed 2005·Granted Sep 1, 2009·5 cites·10 claims
- 1381US7427627B2N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compoundsCYCLACEL LTD·Filed 2006·Granted Sep 23, 2008·6 cites·25 claims
- 1480US7576091B2Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinasesCYCLACEL LTD·Filed 2006·Granted Aug 18, 2009·7 cites·17 claims
- 1580US7544689B2Purine derivativesCYCLACEL LTD·Filed 2005·Granted Jun 9, 2009·4 cites·10 claims
- 1680US7262202B2Inhibitors of cyclin dependent kinases as anti-cancer agentCYCLACEL LTD·Filed 2003·Granted Aug 28, 2007·13 cites·41 claims
- 1780US6828106B2Methods and compositions using coiled binding partnersCYCLACEL LTD·Filed 2000·Granted Dec 7, 2004·11 cites·8 claims
- 1879US6992169B2Carrier based drug delivery systemCYCLACEL LTD·Filed 2002·Granted Jan 31, 2006·9 cites·40 claims
- 1978US7902361B2Pyrimidin-4-yl-3, 4-thione compounds and their use in therapyCYCLACEL LTD·Filed 2006·Granted Mar 8, 2011·7 cites·28 claims
- 2078US7388015B2N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compoundsCYCLACEL LTD·Filed 2004·Granted Jun 17, 2008·13 cites·25 claims
- 2176US7449544B2p21 peptidesCYCLACEL LTD·Filed 2003·Granted Nov 11, 2008·11 cites·9 claims
- 2275US7105307B2Compositions and methods for screening for modulators of enzymatic activityCYCLACEL LTD·Filed 2002·Granted Sep 12, 2006·5 cites·34 claims
- 2374US9675631B2Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabineCYCLACEL LTD·Filed 2013·Granted Jun 13, 2017·2 cites·20 claims
- 2472US6852906B2Assay for measuring enzyme activity in vivoCYCLACEL LTD·Filed 2002·Granted Feb 8, 2005·13 cites·19 claims
- 2569US9573951B2Crystalline forms of a purine derivativeCYCLACEL LTD·Filed 2014·Granted Feb 21, 2017·1 cites·5 claims
- 2669US7772207B2Combination of a CDK inhibitor and CS-682 or a metabolite thereofCYCLACEL LTD·Filed 2004·Granted Aug 10, 2010·9 cites·5 claims
- 2768US9133199B2Pyrimidine derivatives as protein kinase inhibitorsCYCLACEL LTD·Filed 2013·Granted Sep 15, 2015·1 cites·14 claims
- 2868US7153931B1Transport vectorsCYCLACEL LTD·Filed 1999·Granted Dec 26, 2006·15 cites·93 claims
- 2965US7612079B22,6,9-substituted purine derivatives and their use in the treatment of proliferative disordersCYCLACEL LTD·Filed 2003·Granted Nov 3, 2009·4 cites·22 claims
- 3065US6465199B1Compositions and methods for monitoring the modification of natural binding partnersCYCLACEL LTD·Filed 1999·Granted Oct 15, 2002·28 cites·9 claims
- 3165US2008249025A1Methods and Means For Inhibition of CDK4 ActivityCYCLACEL LTD·Filed 2008·Application pending·0 cites
- 3260US6569833B1Cyclin dependent kinase binding peptidesCYCLACEL LTD·Filed 1996·Granted May 27, 2003·18 cites·22 claims
- 3360US2003203407A1Compositions and methods for monitoring the phosphorylation of natural binding partnersCYCLACEL LTD·Filed 2003·Application pending·0 cites
- 3458US2009270427A1Purine derivativesCYCLACEL LTD·Filed 2009·Application pending·0 cites
- 3555US7223795B2Modified peptide derivatives and methods of use thereofCYCLACEL LTD·Filed 2003·Granted May 29, 2007·2 cites·19 claims
- 3655US2003104504A1Chemical modificationCYCLACEL LTD·Filed 2002·Application pending·0 cites
- 3752US6962792B1Methods and means for inhibition of Cdk4 activityCYCLACEL LTD·Filed 1997·Granted Nov 8, 2005·11 cites·26 claims
- 3852US2007185134A1Inhibitors of cyclin dependent kinases as anti-cancer agentCYCLACEL LTD·Filed 2006·Application pending·0 cites
- 3952US2006148017A1Compositions and methods for monitoring enzyme activityCYCLACEL LTD·Filed 2005·Application pending·0 cites
- 4051US7166475B2Compositions and methods for monitoring the modification state of a pair of polypeptidesCYCLACEL LTD·Filed 1999·Granted Jan 23, 2007·16 cites·4 claims
- 4151US6242201B1Identification of the P21WaF1-PCNA interaction site and therapeutic applications thereofCYCLACEL LTD·Filed 1995·Granted Jun 5, 2001·14 cites·16 claims
- 4251US2019314396A1Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemiaCYCLACEL LTD·Filed 2019·Application pending·0 cites
- 4349US9872874B2Dosage regimen for sapacitabine and seliciclibCYCLACEL LTD·Filed 2013·Granted Jan 23, 2018·0 cites·11 claims
- 4449US2005222054A1Combination comprising a CDK inhibitor and doxorubicinCYCLACEL LTD·Filed 2004·Application pending·0 cites
- 4549US2019298718A1Dosing regimenCYCLACEL LTD·Filed 2018·Application pending·0 cites
- 4649US2005164976A1Combination of a cdk inhibitor and 5-fu for the tratment of cancerCYCLACEL LTD·Filed 2003·Application pending·0 cites
- 4749US2007269433A1Cell cycle progressional proteinsCYCLACEL LTD·Filed 2006·Application pending·0 cites
- 4847US10927113B2Process for preparing purine derivativesCYCLACEL LTD·Filed 2018·Granted Feb 23, 2021·0 cites·14 claims
- 4947US6613878B1PCNA binding substanceCYCLACEL LTD·Filed 1996·Granted Sep 2, 2003·7 cites·18 claims
- 5047US2013005747A1Method for selecting a cancer therapyCYCLACEL LTD·Filed 2011·Application pending·0 cites
Showing the top 50 of 84 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →